IDXX — IDEXX Laboratories, Inc.

The tape and the fundamentals are pulling in opposite directions, and the tape is winning. As of 2026-09-13 IDXX was at $504.70, down 5.7% in a week, 11.6% in a month, 10.0% in three months and 12.1% in six months, with RSI(14) at 31.58 and price 16.4% below its 200-day SMA. The bear case is not about execution: Q2 2026 revenue rose 9.7% YoY to $1.217B, EPS rose 15.4% to $4.19, operating margin expanded to 35.0% from 33.6%, and management raised FY26 guidance on 2026-08-04. The bear case is (a) softer U.S. veterinary clinic visit volume and cautious consumer spending on routine pet care, which is the funnel for diagnostic testing, and (b) headline revenue growth decelerating to 9.7% in Q2 from 14.3% in Q1 - a comp artifact (Q1 2025 grew only 3.6% YoY while Q2 2025 grew 10.6%), but the market treated it as a trend break. Layer on rate-driven de-rating of premium-multiple compounders and you get a stock that fell ~30%+ from its peak while forward EPS estimates went up. Sentiment is bearish; the business is not.

Revenue is a steady, not a breaking, story. Reported YoY growth ran +13.3% (Q3'25), +14.3% (Q4'25), +14.3% (Q1'26), then +9.7% (Q2'26) - but quarterly YoY on this name is badly distorted by comps (Q1'25 was +3.6%, Q2'25 was +10.6%). Two-year stacked revenue CAGR is remarkably stable across the last four quarters: Q3'25 +20.7%, Q4'25 +21.0%, Q1'26 +18.3%, Q2'26 +21.2% cumulative over two years, i.e. roughly 9-10% compounding per year, unaffected by the headline Q2 deceleration. Margins are expanding, not compressing: gross margin 64.0% in Q2'26 vs 62.6% in Q2'25; operating margin 35.0% vs 33.6% (+140bps); net margin 27.8% vs 26.5%. Operating margin has expanded YoY in each of the last four reported quarters (Q3'25 32.1% vs 31.2%; Q4'25 28.9% vs 27.4%; Q1'26 31.8% vs 31.7%; Q2'26 35.0% vs 33.6%). EPS growth is decelerating at the margin - +21.4% (Q3'25), +17.6% (Q4'25), +16.6% (Q1'26), +15.4% (Q2'26) - from high-teens toward mid-teens, consistent with a maturing compounder, not a deteriorating one. Cash generation is strong and high-quality: TTM free cash flow of $1.251B (Q2'26 $322.5M, Q1'26 $234.3M, Q4'25 $322.6M, Q3'25 $371.2M) versus $774.3M in the prior-year TTM window, and the accruals ratio of -0.25% as of 2026-06-30 means cash flow is running ahead of reported net income (the healthy direction). Verdict: stable ~10% revenue / ~15% EPS compounding with modest deceleration and margin expansion - a valuation de-rating story, not a fundamental inflection point in either direction.

Cheap against its own history, fair-to-slightly-cheap in absolute terms. As of 2026-09-13: TTM P/E 35.4x (EPS $14.229) vs a 5-year average of 54.0x - a ~34% discount; P/S 8.74x vs a 5-year average of 12.3x - a ~29% discount. Forward P/E on the next-FY EPS estimate of $14.771 is 34.2x; on my ~$15.75 next-twelve-months EPS estimate it is ~32.1x, against expected FY26 EPS growth of ~13.0% (FY25 actual $13.07 -> FY26E $14.77). That is a forward PEG of roughly 2.4-2.6 and a reported TTM PEG of 2.00 - not statistically cheap, but not demanding for a business with 40.3% ROIC, 32% TTM operating margin, 62.4% gross margin, a net-debt position of just ~$103M (cash $196.9M vs LT debt $299.9M) and 3.1% TTM FCF yield. The absolute ratios the screener punishes - P/B of 25.1x, P/C of 207x, EV/EBITDA of 25.7x - are structural artifacts of an asset-light, buyback-heavy, low-capex model (Q2'26 capex was just $24.6M on $347.2M of operating cash flow), not signs of distress. Rich on P/B and EV/EBITDA, cheap on P/E and P/S versus its own range: net, I'd call IDXX modestly cheap for the quality on offer.

This is a textbook multiple-compression setup, and the gap is the whole investment case. Between the Q2 2026 print on 2026-08-04 (revenue +9.7%, EPS +15.4%, FY guidance raised) and 2026-09-13, the stock kept falling to a 52-week low of $500.61 - the 'E' went up and the 'P/E' went down, from the mid-50s average to 35.4x TTM / ~32x NTM. The market is pricing either (a) a permanent reset of the multiple toward the low-30s for a 10% grower, or (b) a real risk that U.S. clinic visit softness eventually drags diagnostics utilization and recurring consumable pull-through. If Q3 2026 (late October/early November) validates the raised guidance and shows visit trends stabilizing, the earnings base plus a stable-to-modestly-higher multiple creates a mechanically large return; if visits deteriorate further, 32x can become 28x and the stock can go lower regardless of EPS delivery. Practically: you are not paying for a turnaround in the numbers - you are paying for a turnaround in the multiple, and you get paid to wait via continued ~15% EPS compounding and buybacks. Analyst targets (FMP consensus $665 from 2 trackers; the research brief cites a $698-$747 cluster) imply 32-48% upside but effectively assume exactly that re-rating - treat them as a bull case, not a base case.

Clearly bearish trend with no reversal signal yet. As of 2026-09-13: RSI(14) 31.58 - approaching but not yet in oversold territory (<30); price 6.8% below the 20-day SMA, 9.23% below the 50-day SMA, and 16.37% below the 200-day SMA; returns of -5.73% (1 week), -11.55% (1 month), -10.02% (3 months) and -12.05% (6 months). The stock closed at $504.70 on 2026-09-13 against a previous close of $506.53, having printed a fresh 52-week low at $500.61 - so it is sitting directly on round-number support with no base, no higher low, and no positive RSI divergence. Entry-timing implication: this is a falling knife with a fundamentals cushion, not a technical entry. A disciplined approach would wait for RSI to reclaim and hold above ~40-45 and for price to reclaim the 20-day SMA before initiating; if support at $500 breaks decisively, the next air pocket toward the high $400s is a real possibility, and there is no reason to front-run that with 9% implied upside to my fair value and 32% to the analyst consensus.

• U.S. veterinary clinic visit volume and discretionary pet-care spending - the single biggest swing factor. Soft visit growth restricts the funnel for in-clinic diagnostics and recurring consumable pull-through, and it is a consumer-confidence phenomenon rather than anything IDEXX controls.
• Interest rates and the discount rate applied to premium-multiple compounders - a beta of 1.538 and a 35x+ earnings multiple make the stock acutely sensitive to rate expectations; much of the de-rating from a 54x 5-year average P/E to 35x is a macro artifact rather than a business signal.
• Secular 'pet humanization' tailwind - rising pet insurance penetration, higher willingness to pay for advanced diagnostics, and aging pet populations support long-run volume, and this tailwind has not reversed even as near-term visits softened.
• Competitive and pricing dynamics in companion-animal diagnostics - Zoetis (Vetscan), Mars/Antech and other point-of-care and reference-lab entrants compete for the same clinic wallet, and reference-lab pricing and menu breadth are ongoing competitive levers.
• Foreign exchange and international demand - IDEXX derives a substantial share of revenue outside the U.S., so dollar strength is a translational headwind, and international clinic economics can diverge sharply from the U.S. trajectory.

• Q3 2026 earnings (expected late October/early November 2026) - the single most important event: whether raised FY26 guidance is tracking, whether Companion Animal Group recurring diagnostics growth holds, and whether U.S. clinic visit trends show any stabilization.
• Commercial ramp of the dual-species point-of-care NT-proBNP cardiac test launched on 2026-08-11, plus the recent fecal/antigen menu additions - per-visit menu expansion is the primary lever to grow diagnostics revenue per clinic even if visit volumes stay soft.
• Follow-through on the 2026-08-13 Investor Day medium-term margin-expansion framework - any quantified targets or capital-allocation commitments would give the market a reason to underwrite a multiple above the current ~32x NTM.
• Multiple re-rating optionality - with the stock at 35.4x TTM versus a 54.0x 5-year average, even a partial normalization of the multiple on unchanged earnings is a large return driver; easing rate expectations or an improving consumer backdrop are the triggers.
• Continued free cash flow conversion and buybacks - $1.251B TTM FCF against a $39.8B market cap funds steady share retirement that mechanically lifts per-share earnings growth above net income growth.

• Prolonged U.S. veterinary visit weakness - if clinic traffic does not stabilize, diagnostics utilization and recurring consumable pull-through stay suppressed and the ~10% revenue CAGR compresses toward mid-single digits.
• Multiple risk is the dominant risk - at ~32x NTM earnings with ~10% revenue growth, roughly 2.4-2.6x forward PEG, there is no valuation cushion for a guidance miss; a further de-rating to the high-20s multiple would cause meaningful downside even with intact earnings.
• Competitive incursion into point-of-care and reference-lab diagnostics from Zoetis, Mars/Antech or retail/DTC entrants - IDEXX's in-clinic instrument installed base is the moat, but it is contestable and the switching dynamics run through multi-year instrument placements.
• Technical breakdown risk - as of 2026-09-13 the stock sat at $504.70 just above its 52-week low of $500.61, below every major moving average, with RSI at 31.58; a decisive break of $500 removes the last visible support level.
• Macro/FX and rate sensitivity - dollar strength on international revenue and any renewed rise in discount rates hits a high-multiple, internationally exposed name disproportionately.

IDEXX is a genuinely elite business - 40.3% ROIC, 32% operating margin, 62.4% gross margin, negative accruals (cash earnings ahead of reported profit), a net-debt position of only ~$103M, and stable ~10% revenue / ~15% EPS compounding that is being priced as if it were broken. At $504.70 on 2026-09-13 you are buying that franchise at 35.4x TTM and ~32x NTM earnings - a ~34% discount to its own 5-year average P/E of 54x - which is a fair-to-attractive price, not a bargain, and it comes with a real risk that the multiple keeps compressing until U.S. clinic visit trends visibly turn. My honest read: this is a good long-term entry for a patient investor who can tolerate a drawdown into the high $400s, but the technicals offer zero confirmation (RSI 31.58, below all moving averages, at a 52-week low), so there is no urgency to buy before the Q3 print - and anyone expecting the analyst-consensus 32%+ upside is really betting on multiple re-rating, not on earnings, which already look fine.

Primary method: 35x next-twelve-months EPS of ~$15.75 - the midpoint between FY2026E EPS of $14.771 (analyst consensus) and an FY2027E of roughly $16.7 (13% growth, in line with recent mid-teens EPS delivery) - giving ~$551, rounded to $550. A 35x multiple is a deliberate discount to IDXX's 5-year average P/E of 54.0x (justified by slower ~10% revenue growth, higher rates, and the unresolved clinic-visit headwind) but a premium to the current ~32x NTM, warranted by 40.3% ROIC, 32% operating margin, negative accruals, and a near-net-cash balance sheet. Cross-check: a simplified DCF using TTM free cash flow of $1,250.6M, 12% FCF growth for five years, 4% terminal growth, and an 8.5-8.75% discount rate yields roughly $490-$515 per share, so the blended fair value lands in the mid-$500s; at $550 the implied FCF yield is ~2.8% against double-digit FCF growth, and the implied forward P/E of ~35x on FY2027E EPS is consistent with a 2.3-2.5x PEG - a fair, not heroic, price for this quality.